WC
SRPT icon

Wexford Capital’s Sarepta Therapeutics SRPT Stock Holding History

Wexford Capital’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4,645
Closed -$100K – 362
2025
Q4 		$100K Buy
+4,645
New +$97.9K 0.02% 247
2018
Q2 		– Sell
-39,400
Closed -$2.92M – 147
2018
Q1 		$2.92M Buy
+39,400
New +$2.63M 0.21% 46
2016
Q4 		– Sell
-38,460
Closed -$2.36M – 300
2016
Q3 		$2.36M Buy
+38,460
New +$1.16M 0.39% 69

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Wexford Capital's SRPT Position: Q1 2026 in Review

Wexford Capital sold out of Sarepta Therapeutics (SRPT) in Q1 2026, closing a stake of 4,645 shares — an estimated $100K sold.

Wexford Capital first reported a position in SRPT in Q3 2016 and held it in 3 quarters. The position peaked at $2.92M in Q1 2018. 344 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

  • Wexford Capital reported no remaining Sarepta Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Wexford Capital sold 4,645 Sarepta Therapeutics shares in Q1 2026, an estimated $100K.
  • Wexford Capital first reported a position in Sarepta Therapeutics in Q3 2016 and held it in 3 quarters.
  • Wexford Capital's Sarepta Therapeutics position peaked at $2.92M in Q1 2018.
  • 344 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on Wexford Capital's 13F filing for Q1 2026, filed 15 May 2026.